This secondary analysis of a randomized clinical trial examines the effect of androgen deprivation therapy (ADT) during radiotherapy in patients who were classified as having either favorable intermediate-risk or unfavorable intermediate-risk prostate cancer.
JAMA network open. 2020 Sep 01*** epublish ***
Zachary S Zumsteg, Daniel E Spratt, Timothy J Daskivich, Mourad Tighiouart, Michael Luu, Joseph P Rodgers, Howard M Sandler
Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Department of Radiation Oncology, University of Michigan, Ann Arbor., NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.